Early Adverse Effects after COVID-19 Vaccine in Children and Adolescents with Psychiatric Disorders
Open Access
- 27 November 2024
- journal article
- Published by Yildirim Beyazit University Yenimahalle Education and Research Hospital in Türk Tıp Dergisi
- Vol. 9 (3) , 114-125
Abstract
Objective: Vaccines for COVID-19 have reduced the severity of the infection and prevented deaths. Parents of children on psychopharmacological medications for psychiatric disorders were also referred to the hospital to learn whether the vaccine was safe for their children. It is not known until this period how chronic psychopharmacological drug use will interact with the vaccine. This study aimed to examine the early adverse effects of COVID-19 vaccines in children and adolescents aged 12-18 who have chronic psychiatric disorders and use psychopharmacological medications. Method: Post-vaccine short-term effects of 88 patients aged 12-18, who were followed up in the child and adolescent psychiatry clinic due to chronic psychiatric disorders and were using psychopharmacological medications, were monitored and compared with 88 vaccinated healthy controls. Results: Of the 88 patients, 80 (90.9%) were vaccinated with BNT162b2 (BioNTech) as the healthy control group; 8 (9.1%) were with Sinovac. Seventy-six (86.3%) of all patients were vaccinated with the second, and 21 (24%) were with the third dose. These were 83-second and 26-third doses for the control group. From all 45.4% of the patients were using antipsychotics. The cases were examined on the fourth and seventh days after vaccination. While the most frequently reported adverse effects after the first BNT162b2 dose in the patient group on the fourth day after vaccination were local pain (58.8%), fatigue (16.3%), redness (12.5%), and headache (11.3%), side affects first Sinovac dose in the patient group were local pain (75.0%), redness (25.0%), fatigue (25.0%). There was no significant difference between the patient and control groups receiving the BNT162b2 or Sinovac vaccine regarding adverse ffects on the fourth day. At the same time, in comparisons between patients diagnosed with psychiatric disorders, no statistical difference was found in terms of early adverse effects between the patients with and without antipsychotic use. Discussion: Our study shows that the vaccines mentioned in children and adolescents with psychiatric disorders are as safe and tolerable in terms of short-term side effects as in healthy individuals. This knowledge will be crucial in guiding evidence-based clinical decision-making and ensuring the safety of children and adolescents with psychiatric disorders.Keywords
This publication has 23 references indexed in Scilit:
- Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in EnglandNature Communications, 2024
- Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 YearsJAMA Pediatrics, 2023
- It is time to improve the acceptance of COVID‐19 vaccines among people with chronic diseases: A systematic review and meta‐analysisJournal of Medical Virology, 2023
- Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysisWorld Journal of Pediatrics, 2023
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- Education and mental health: good reasons to vaccinate childrenThe Lancet, 2021
- COVID-19 vaccination for people with severe mental illness: why, what, and how?The Lancet Psychiatry, 2021
- Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort studyThe Lancet Psychiatry, 2020
- The Epidemiology and Burden of Child and Adolescent Mental Disorder2007
- Effects of antipsychotic drugs on cytokine networksJournal of Psychiatric Research, 2000